Abstracts tagged "bone biology"

Abstract Number: 2116 • ACR Convergence 2025
Romosozumab in Multiple Myeloma Patients at High Risk of Fracture
Giovanni Adami¹, Mariana Diz Lopes², Martina Tinelli², Angela Bonalumi², Ombretta Viapiana² and Maurizio Rossini², ¹University of Verona, Italy, Verona, Italy, ²University of Verona, Verona, Italy
Background/Purpose: Bone damage is a key feature of multiple myeloma (MM). Romosozumab (ROMO), a sclerostin inhibitor, has dual anabolic and antiresorptive properties and may offer…
Abstract Number: 1993 • ACR Convergence 2025
Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Tingting Zhang¹, Christian W. Mende², Ashraf El-Meanawy³, Michael Pillinger⁴, Kaiding Zhu⁵, Bradley Marder⁶ and Brian Lamoreaux⁷, ¹Amgen, Inc., Thousand Oaks, ²University of California San Diego, San Diego, CA, ³Medical College of Wisconsin, Milwaukee, WI, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Amgen, Inc., San Francisco, CA, ⁶AMGEN, Inc, Denver, CO, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Gout may increase the risk of cardiovascular events (CVEs) and bone fractures through urate deposition and chronic inflammation1,2. However, the additional effects of uncontrolled…
Abstract Number: 1815 • ACR Convergence 2025
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Brittney Newby¹, Timothy Brandon¹, Pamela Weiss² and E. John Wherry³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
Abstract Number: 1142 • ACR Convergence 2025
Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD
Sara Tedeschi¹, Priyanka Kushwaha², Muneet Gill², Julia F. Charles³ and Ellen M. Gravallese⁴, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ³Department of Orthopedic Surgery & Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: CPPD has been associated with osteopenia of the metacarpal heads and a 2x increased risk for fracture of the wrist, hip, humerus or pelvis.…
Abstract Number: 0872 • ACR Convergence 2025
Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.
Priyanka Kushwaha¹, Albert Tai², Catherine Manning³, Yeon Suk Yang⁴, Jae-Hyuck Shim⁴ and Ellen M. Gravallese⁵, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Department of Immunology, Tufts University School of Medicine, Boston, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴²Department of Medicine/Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Schnurri-3 (SHN3) is an adaptor protein and a negative regulator of osteoblast (OB) function. Its inhibition prevents bone loss and joint erosion in models…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…
Abstract Number: 0346 • ACR Convergence 2025
Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
José Rodríguez gago¹, Carolina Tornero², Lina León³, María Luisa González-Casaus³, Luisa Fernanda Giraldo³, Gloria del Peso³, Diego Garrido³, Teresa López³, Mónica Coronado³, María Auxiliadora Bajo⁴, Sara García³, María Gema Serrano³, Marta Ossorio³, Alejandro Balsa³ and Pilar Aguado³, ¹Hospital Universitario La Paz, MADRID, ²Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Hospital Universitario de la Princesa - ISS Princesa, Madrid, Spain
Background/Purpose: Chronic kidney disease (CKD) is linked to increased vascular comorbidity and fracture risk. This study aims to assess bone status in CKD patients versus…
Abstract Number: 0098 • ACR Convergence 2025
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
Archita Srinath¹, Sungsin Jo², Daniele Mauro³, Mariia Korshko⁴, Mansi Aparnathi⁵, Shaghayegh Foroozan Boroojeni⁶, Tae-Hwan Kim⁷, Francesco Ciccia⁸ and Nigil Haroon⁹, ¹University of Toronto, Toronto, ON, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Campania, Italy, Naples, Italy, ⁴UHN, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network/University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸University of Campania, Naples, Italy, ⁹Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…
Abstract Number: 0095 • ACR Convergence 2025
Effect of JAK Inhibitors on Osteoblast Differentiation
Toshihiro Tanioka¹ and Takeo Isozaki², ¹Graduate School of Pharmacy, Showa Medical University, Shinagawa-ku,Tokyo, Tokyo, Japan, ²Graduate School of Pharmacy, Showa Medical University, Tokyo, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and joint destruction. Among the therapeutic strategies available, Janus kinase (JAK) inhibitors have…
Abstract Number: 2117 • ACR Convergence 2024
The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260
Camille Ghio, Robinson Gravier-Dumonceau, Pierre Lafforgue, Roch Giorgi and Thao Pham, Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…
Abstract Number: 2131 • ACR Convergence 2024
Role of LECT2 in the Regulation of Bone Metabolism In Vitro and In Vivo
Myeung-Su Lee¹, Chang-hoon Lee², CHONG HYUK CHUNG¹, Ju-Young Kim³, Yoon-Hee Cheon⁴, So Young Eun³ and Gyeung Do Park³, ¹Wonkwang University Hospital, Iksan, South Korea, ²Wonkwang University Hospital, Iksan Jeonbuk, South Korea, ³Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Republic of Korea, ⁴Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Cholla-bukto, Republic of Korea
Background/Purpose: Leucocyte cell derived chemotaxin 2 (LECT2) is a hepatokine produced in liver cells, secreted into the circulation, and acts as a hormone throughout the…
Abstract Number: 2133 • ACR Convergence 2024
Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better
Zeqin Wen¹, Yilun Wang¹, Xiaoxiao Li², Yuqing Zhang³, Junqing Xie⁴, Houchen Lyu⁵, Changjun Li², Jie Wei⁶, Guanghua Lei⁷ and Chao Zeng⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ²Central South University, Changsha, China (People's Republic), ³Massachusetts General Hospital, Quincy, MA, ⁴University of Oxford, Oxford, United Kingdom, ⁵Central South University, Beijing, China, ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic)
Background/Purpose: High low-density lipoprotein cholesterol (LDL-C) is a major risk factor for fracture; however, whether LDL-C lowering induced by statins is associated with decreased fracture…
Abstract Number: 2134 • ACR Convergence 2024
PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo
CHONG HYUK CHUNG¹, Myeung-Su Lee¹, Chang-hoon Lee², Ju-Young Kim³, Yoon-Hee Cheon⁴, So Young Eun³ and Gyeung Do Park³, ¹Wonkwang University Hospital, Iksan, South Korea, ²Wonkwang University Hospital, Iksan Jeonbuk, South Korea, ³Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Republic of Korea, ⁴Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Iksan, Cholla-bukto, Republic of Korea
Background/Purpose: Peroxisomal biogenesis factor 5 (PEX5) is essential for regulating peroxisome function by recognizing and transporting peroxisome target sequence receptor substrate proteins to peroxisomes. PEX5…
Abstract Number: 2145 • ACR Convergence 2024
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.
Daniel Ramos Castro¹, SAMUEL LEAL², Elena Grau García³, JOSE ELOY OLLER RODRIGUEZ⁴, José Ivorra-Cortés⁵, Carmen Riesco Barcena⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Laura Mas Sánchez⁹, Alba Torrat noves¹⁰, Belén Villanueva Mañés¹¹, Iago Alcántara Álvarez¹², Andrés Pérez Hurtado¹, Miguel Simeo Vinaixa¹¹ and Jose A Román-Ivorra¹³, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Hospital La Fe, Valencia, Spain, ³HUP La Fe, Valencia, Spain, ⁴HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁵Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁶Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valéncia, Comunidad Valenciana, Spain, ¹³Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder (90% autosomal dominant) characterized by a disruption in type 1 collagen or proteins associated with…
Abstract Number: 2528 • ACR Convergence 2024
Activation of the Hes1/Piezo1 Pathway Promotes Mechanical Stress Response and Prevents Glucocorticoid-induced Osteoporosis
Nagahiro Ochiai¹, Yuki Etani², Takaaki Noguchi², Taihei Miura², Takuya Kurihara², Yuji Fukuda², Hidetoshi Hamada², Keisuke Uemura², Kazuma Takashima², Masashi Tamaki², Teruya Ishibashi², Shohei Ito³, Satoshi Yamakawa², Takashi Kanamoto², Seiji Okada², Ken Nakata² and Kosuke Ebina², ¹Taisho Pharmaceutical Co., Ltd., Saitama, Saitama, Japan, ²Osaka University, Suita, Japan, ³Taisho Pharmaceutical, Co., Ltd., Saitama, Japan
Background/Purpose: This study investigated the diminished expression of Piezo1 (Piezo-type mechanosensitive ion channel component 1), a mechanosensitive receptor, in bone tissues of both patients and…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].